New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2014
09:10 EDTZLC, SM, MFRM, UCTT, SUNE, SCTY, DVN, GRMN, CG, ACT, CHTP, TS, X, SIG, OCROn The Fly: Pre-market Movers
UP AFTER EARNINGS: Garmin (GRMN), up 12%... Carlyle Group (CG), up 6.5%... Ultra Clean (UCTT), up 18%... SunEdison (SUNE), up 3%. ALSO HIGHER: Zales (ZLC), up 40% after Signet Jewelers (SIG) to acquire the company for $21.00 per share cash. Signet Jewelers is up 11.6% after the news... Chelsea Therapeutics (CHTP), up 33.5% after Northera granted FDA accelerated approval... Actavis (ACT), up 1.4% after reiterating standalone FY14 adjusted EPS view, shares upgraded at Goldman... Devon Energy (DVN), up 1.8% after earnings, announcing sale of Canadian conventional assets to Canadian Natural Resources (CNQ). DOWN AFTER EARNINGS: Mattress Firm (MFRM), down 10%... Omnicare (OCR), down 4.3%. ALSO LOWER: U.S. Steel (X), down 4.4%, Tenaris down 5.4% after U.S. excludes South Korea from steel tubing tariffs... SolarCity (SCTY), down 1.4% following downgrade at RW Baird... SM Energy (SM), down 11% after earnings, downgrades at Tudor Pickering and KeyBanc.
News For ZLC;SIG;X;TS;CHTP;ACT;CG;GRMN;DVN;SCTY;SUNE;UCTT;MFRM;SM;OCR From The Last 14 Days
Check below for free stories on ZLC;SIG;X;TS;CHTP;ACT;CG;GRMN;DVN;SCTY;SUNE;UCTT;MFRM;SM;OCR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 11, 2014
07:19 EDTSIGSignet Jewelers price target raised to $140 from $125 at BofA/Merrill
Subscribe for More Information
06:15 EDTOCROmnicare upgraded at Goldman
Subscribe for More Information
05:32 EDTOCROmnicare upgraded to Buy from Neutral at Goldman
Subscribe for More Information
September 10, 2014
16:13 EDTTSTenaris upgraded to Overweight from Equal Weight at Morgan Stanley
Subscribe for More Information
11:37 EDTGRMNGarmin bounces back, Fossil continues slide after Apple Watch unveiled
Subscribe for More Information
09:38 EDTXActive equity options trading on open
Subscribe for More Information
09:22 EDTSUNEOn The Fly: Pre-market Movers
HIGHER: Twitter (TWTR), up 2.8% after upgraded at UBS... SunEdison (SUNE), up 2.7% after Google (GOOG) to provide $145M investment in the company's Regulus solar plant... Camtek (CAMT), up 15% after receiving new orders of $3.0M from large OSAT... Doral Financial (DRL), up 12.5% after announcing sale of approximately $430M in assets... Imperva (IMPV), up 1.5% after upgraded at Oppenheimer... Mandalay Digital (MNDL), up 13.7% after updating its guidance. UP AFTER EARNINGS: Land's End (LE), up 8.7%... Palo Alto (PANW), up 4.4%. LOWER: eBay (eBAY), down 2.6% after downgraded at Piper Jaffray following yesterday's launch of Apple Pay (AAPL)... Mobileye (MBLY), down 2.5% after downgraded at Deutsche Bank... Krispy Kreme (KKD), down 2% after Q2 earnings report... GT Advanced (GTAT), down 7% after downgraded at Goldman and Piper Jaffray... Boyd Gaming (BYD), down 3.3% after downgraded at Morgan Stanley... Urban Outfitters (URBN), down 2% after reporting Q3 SSS were so far in the low single-digits negative... Armada Hoffler (AHH), down 6% after filing to sell 5M shares of common stock... AvalonBay (AVB), down 1.8% after to sell 4.5M shares in a forward sales agreement with Goldman... AngloGold (AU), down 12% after announcing plans to restructure its international mining under a new company and saying equity capital raising being contemplated.
09:02 EDTACTActavis won't see serious long-term impact from rejection, says Sterne Agee
After the FDA's Cardiovascular and Renal Drugs Advisory Committee voted to recommend against approval of Actavis' New Drug Application for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension, Sterne Agee does not thinks the vote is very meaningful to the company's longer-term growth and earnings potential. The firm says that removing the product from its revenue outlook causes its 2018 EPS estimate for the company to drop by less than 1%. The firm still thinks the company can easily reach its 2017 EPS target of about $20. Sterne Agee keeps a $272 price target and Buy rating on the shares.
08:56 EDTACTFDA advisors recommend against approval of Actavis' nebivolol/valsartan combo
Actavis last night confirmed that the FDA's Cardiovascular and Renal Drugs Advisory Committee has voted to recommend against approval of Actavis' New Drug Application for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension. The committee vote was six to four recommending against approval. The committee recommendation is not binding on the FDA, which makes the final decision regarding approval. Actavis expects FDA action on its NDA for the fixed-dose combination of nebivolol and valsartan by the fourth quarter of 2014. Actavis' Senior VP, Global Brands Research and Development, David Nicholson, said, "Although we are disappointed in the Committee's recommendation regarding the fixed-dose combination of nebivolol and valsartan, we remain fully committed to supporting the NDA for this important potential new treatment option for patients with hypertension. We remain confident in the safety and efficacy of the combination of these two widely used and well-tolerated treatments, and we look forward to working with the FDA as it completes its review." Shares of Actavis are down more than 2% in pre-market trading following yesterday's committee recommendation.
08:48 EDTGRMNGarmin unlikely to be derailed by Apple Watch, says Oppenheimer
Oppenheimer does not view Apple Watch as "a category killer" in the running or fitness band markets. The firm says that the necessity of pairing the Apple Watch with an iPhone, along with Apple Watch's use of a built-in optical hear rate sensor which is likely to be prone to malfunction are disadvantages. Additionally, Apple Watch's price is much higher than the prices that Garmin (GRMN) charges for its watches, while the Apple Watch's battery life is likely much shorter, according to Oppenheimer. The firm keeps an Outperform rating on Garmin.
07:18 EDTGRMNApple Watch does not compete with Garmin, says Citigroup
Subscribe for More Information
07:04 EDTSUNEGoogle to provide $145M investment in SunEdison's Regulus solar plant
Subscribe for More Information
September 9, 2014
17:06 EDTACTFDA panel votes against Actavis blood pressure pill, Bloomberg says
FDA advisers said that Actavis's experimental pill that combines two existing drugs to lower high blood pressure doesn’t provide a clinically meaningful benefit over the two drugs alone, says Bloomberg. The advisory panel voted 6 to 4 against recommending the treatment, added Bloomberg. Shares of Actavis are trading down almost 1% in after-hours trading. Reference Link
14:03 EDTGRMNGarmin down 3% after Apple confirms launch of Apple Watch
Subscribe for More Information
10:18 EDTACTDollar General listed among 5 largest long positions by Jana Partners
Subscribe for More Information
September 8, 2014
09:14 EDTSCTYSolarCity weak since competitor IPO prospectus, says Roth Capital
Subscribe for More Information
06:00 EDTCGCarlyle Group closes Carlyle Asia Partners IV fund
Carlyle Group announced the final close of Carlyle Asia Partners IV at $3.9B, more than 50% larger than its predecessor fund CAP III. Carlyle’s Asia buyout funds make control and significant minority investments in well established companies across the Asia ex-Japan region. The final close of CAP IV, which exceeded its target of $3.5B, brings the firm’s assets under management in Asia funds, including Japan, to $13.6B across its buyout, growth, RMB and real estate funds. Reference Link
September 5, 2014
16:45 EDTMFRMMarket ends week little changed after mixed economic data
Subscribe for More Information
10:05 EDTACTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at ISI Group... Akamai (AKAM) initiated with a Buy at UBS... Alexion (ALXN) initiated with a Buy at SunTrust... Allegion (ALLE) initiated with a Buy at Buckingham... Allergan (AGN) initiated with a Buy at ISI Group... Aviat Networks (AVNW) initiated with a Neutral at H.C. Wainwright... Celgene (CELG) initiated with a Buy at SunTrust... EZCORP (EZPW) initiated with a Hold at Jefferies... Eaton (ETN) initiated with a Neutral at Buckingham... Emerson (EMR) initiated with a Neutral at Buckingham... HMS Holdings (HMSY) initiated with an Overweight at Stephens... Incyte (INCY) initiated with a Buy at SunTrust... Ingersoll-Rand (IR) initiated with a Neutral at Buckingham... Insmed (INSM) initiated with an Outperform at Cowen... Intercept (ICPT) initiated with an Outperform at Cowen... Johnson & Johnson (JNJ) initiated with an Outperform at BMO Capital... Lennox (LII) initiated with a Neutral at Buckingham... Mylan (MYL) initiated with a Hold at ISI Group... Orion Engineered Carbons (OEC) initiated with a Buy at Goldman... Parker-Hannifin (PH) initiated with a Buy at Buckingham... Pentair (PNR) initiated with a Neutral at Buckingham... Pharmacyclics (PCYC) initiated with a Neutral at SunTrust... Rockwell Automation (ROK) initiated with a Neutral at Buckingham... Sabre (SABR) initiated with an Outperform at Oppenheimer... Santander Consumer (SC) initiated with a Buy at Jefferies... Springleaf (LEAF) initiated with a Buy at Jefferies... Susser Petroleum (SUSP) initiated with a Neutral at Credit Suisse... Teva (TEVA) initiated with a Buy at ISI Group... Valeant (VRX) initiated with a Buy at ISI Group... WESCO (WCC) initiated with a Neutral at Buckingham... Watsco (WSO) initiated with a Neutral at Buckingham... Weyerhaeuser (WY) initiated with a Neutral at JPMorgan... World Acceptance (WRLD) initiated with a Hold at Jefferies.
08:00 EDTACTActavis announces FDA acceptance of the NDA filing for ceftazidine-avibactam
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use